Personalis, Inc. (PSNL)
Personalis, Inc. (PSNL) from its SEC filings: 2025 revenue $69.6 million (-18% vs the year before), net margin -117%, free cash flow -$79.5 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Services-Medical Laboratories |
| Revenue (2025) | $69.6 million |
| Revenue growth | -18% |
| Net income | -$81.3 million |
| Net margin | -116.7% |
| Free cash flow | -$79.5 million |
| Diluted EPS | $-0.91 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +30% |
| Cash | $94.0 million |
| Long-term debt | $18.0 million |
| Share count, 1 year | +20% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.